Metabolic profile of first and second generation antipsychotics among Chinese patients

Psychiatry Research

Volumn 185, Issue 3, 2011, Pages 456-458

  Lee, Edwin ^a   Chow, Lai Yin ^a   Leung, Chi Ming ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chlorpromazine; Dyslipidemia; Haloperidol; Olanzapine; Risperidone; Trifluoperazine; Ziprasidone

Indexed keywords

CHLORPROMAZINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; AGE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79251600810     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.04.050     Document Type: Article

References (24)

1. Aichhorn W., Whitworth A.B., Weiss E.M., Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Safety 2006, 29:587-598.
2. Almeras N., Dunayevich E. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. Journal of Clinical Psychiatry 2004, 65:557-564.
3. Barbui C., Nosè M., Bindman J., Schene A., Becker T., Mazzi M.A., Kikkert M., Camara J., Born A., Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology 2005, 25:521-526.
4. Basu R., Breda E., Oberg A.L., Powell C.C., Dalla Man C., Basu A., Vittone J.L., Klee G.G., Arora P., Jensen M.D., Toffolo G., Cobelli C., Rizza R.A. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003, 52:1738-1748.
5. Bhopal R., Hayes L., White M., Unwin N., Harland J., Ayis S., Alberti G. Ethnic and socio-economic inequalities in coronary heart disease, diabetes and risk factors in Europeans and South Asians. Journal of Public Health Medicine 2002, 24:95-105.
6. Casey D.E. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. American Journal of Medicine 2005, 118:15S-22S.
7. Chen Q., Cai Z.J., Mao P.X., Zhai Y.M., Mitchell P.B., Tang Y.L. Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study. Journal of Psychiatric Research 2008, 43:124-128.
8. Chong M.Y., Tan C.H., Fujii S., Yang S.Y., Ungvari G.S., Si T., Chung E.K., Sim K., Tsang H.Y., Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry and Clinical Neuroscience 2004, 58:61-67.
9. Guha P., Roy K., Sanyal D., Dasgupta T., Bhattacharya K. Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics. Journal of the Indian Medical Association 2005, 103:660-664.
10. Henderson D.C. Schizophrenia and comorbid metabolic disorders. Journal of Clinical Psychiatry 2005, 66:11-20.
11. Huang T.L., Chen J.F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophrenia Research 2005, 80:55-59.
12. Jin H., Meyer J.M., Jeste D.V. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 2004, 71:195-212.
13. Ko G.T., Chan J.C. Burden of obesity--lessons learnt from Hong Kong Chinese. Obesity Review 2008, 9:35-40.
14. Ko G.T., Wai H.P., Tang J.S. Effects of age on plasma glucose levels in non-diabetic Hong Kong Chinese. Croatian Medical Journal 2006, 47:709-713.
15. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
16. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry 2003, 160:290-296.
17. Melkersson K., Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004, 64:701-723.
18. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 2002, 63:425-433.
19. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety 2005, 28:191-208.
20. Sernyak M.J. Implementation of monitoring and management guidelines for second-generation antipsychotics. Journal of Clinical Psychiatry 2007, 68:14-18.
21. Subramaniam M., Ng C., Chong S.A., Mahendran R., Lambert T., Pek E., Huak C.Y. Metabolic differences between Asian and Caucasian patients on clozapine treatment. Human Psychopharmacology 2007, 22:217-222.
22. Tarricone I., Casoria M., Gozzi B.F., Grieco D., Menchetti M., Serretti A., Ujkaj M., Pastorelli F., Berardi D. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. Biomedical Centre Psychiatry 2006, 6:11.
23. Van der Kooy K., Seidell J.C. Techniques for the measurement of visceral fat: a practical guide. International Journal of Obesity and Related Metabolic Disorders 1993, 17:187-196.
24. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.